title: A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletion.
abstract: Invariant Natural Killer T (iNKT) cells are a subset of T cells recognizing glycolipid antigens presented by CD1d. Human iNKT cells express a conserved T cell receptor (TCR)-α chain (Vα24-Jα18) paired with a specific beta chain, Vβ11. The cells are both innate-like, with rapid cytokine release, and adaptive-like, including thymic positive selection. Over activation of iNKT cells can mediate tissue injury and inflammation in multiple organ systems and play a role in mediating the pathology associated with clinically important inflammatory diseases. At the same time, iNKT cell activation can play a role in protecting against infectious disease and cancer or modulate certain autoimmune diseases through its impact on both the innate and adaptive immune system. This suggests that approaches to cause iNKT cell reduction and/or depletion could treat inflammatory diseases while approaches to promote activation may have therapeutic potential in certain infections, cancer or autoimmune disease. This report summarizes the characterization of a humanized monoclonal depleting antibody (NKTT120) in the cynomolgus macaque. NKTT120 is being developed to treat iNKT mediated inflammation that is associated with chronic inflammatory conditions like sickle cell disease and asthma. NKTT120 binds to human iTCRs and to FCγRI and FCγRIII and has been shown to kill target cells in an ADCC assay at low concentrations consistent with the FCγR binding. iNKT cells were depleted within 24 hours in cynomolgus macaques, but T cell, B cell, and NK cell frequencies were unchanged. iNKT cell recovery was dose and time dependent. T cell dependent antigen responses were not impaired by NKTT120 mediated iNKT depletion as measured by response to KLH challenge. NKTT120 administration did not induce an inflammatory cytokine release at doses up to 10 mg/kg. These data support the use of NKTT120 as an intervention in inflammatory diseases where iNKT reduction or depletion could be beneficial.
authors.affiliation: NKT Therapeutics, Inc., Waltham, Massachusetts, United States of America.
authors.forename: Felix
authors.initials: F
authors.lastname: Scheuplein
authors.forename: Abraham
authors.initials: A
authors.lastname: Thariath
authors.forename: Susan
authors.initials: S
authors.lastname: Macdonald
authors.forename: Alemseged
authors.initials: A
authors.lastname: Truneh
authors.forename: Robert
authors.initials: R
authors.lastname: Mashal
authors.forename: Robert
authors.initials: R
authors.lastname: Schaub
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology*; D000918:Antibody Specificity; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D007249:Inflammation / Q000276:immunology; D008252:Macaca fascicularis; D055611:Natural Killer T-Cells / Q000276:immunology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized